ADVERTISEMENT
France
France’s medtech sector is strong, growing and innovative. Medtech Insight spoke to several French medtech leaders about the unique features and pitfalls their industry may face.
French industry association Gemme has issued a stark warning that recent legislative proposals – including a revision to the country’s clawback mechanism and steeper financial penalties for failing to hold sufficient safety stocks – will “bring about the end of the generic economic model in France.”
Country Life Vitamins launches healthy aging support line as it announces less than half of US consumers in a recent survey were aware of biological processes that affect aging. Groupe Berken and Arctic Biosciences partner to bring to North America herring caviar oil extract in a supplement designed to support optimal health across all life stages.
France’s regulatory agency, which triggered the review, says it believes that the addition of suicidal ideation to the product information for finasteride and reports of cases of completed suicide “seriously alter” the product’s benefit-risk profile.
Monaco-based Sérélys markets pollen-based supplements for a range of women's health issues, including premenstrual syndrome, postpartum discomfort and menopause.
A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.
The French pharma industry body Leem says that the scale of its contribution to health insurance cost savings is undermining the industry’s financial sustainability.
A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.
Escaping A Regulatory Labyrinth: France Adopts Streamlined Approach To Food Supplement Notifications
Companies launching food supplements in France must now navigate a new product notification platform. EcoMundo’s Corinne Rayapin discusses why the change is happening and the expected benefits for both industry and consumers.
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.